EU Approves New Long-Acting HIV Prevention Injection: Lenacapavir

New HIV Prevention Drug Approved in EU

• 💉 The European Union has approved Lenacapavir (brand name Yato), a new long-acting treatment for HIV prevention.
• 🎯 This drug offers a significant alternative to daily anti-retroviral tablets, requiring only two injections per year.
• 💡 With 99.9% efficacy, it aims to improve prevention options, especially for vulnerable populations where current methods are insufficient.

Efficacy and Accessibility

• 📈 Lenacapavir has demonstrated high efficacy, potentially transforming the fight against AIDS.
• 🌍 The developer, Gilead Sciences, views this approval as a major milestone in their efforts to end the HIV epidemic.

Cost and Global Access Concerns

• 💰 A significant concern is the high cost of Lenacapavir, potentially exceeding $28,000 per patient annually in the EU.
• 🇺🇸 The drug faced similar criticism for its price tag upon its release in the United States.
• 🔬 Analysis suggests the drug could be manufactured for as little as $25 per year, highlighting a large price disparity.
• 🤝 Gilead has agreements with generic companies for low-cost versions in 120 low-income countries and committed to providing doses for 2 million people.
• ⚠️ Despite these efforts, the World Health Organization estimates that 10 million people need HIV prevention drugs to significantly reduce infections.